Oral Biologics Market Perspective by Comprehensive Analysis, Growth Prediction to 2026 With Key Players Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Rani Therapeutics, Entera Bio, Allergan, Emisphere Technologies, Enteris BioPharma
Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parental route and only guanylate cyclase-c agonist class of drug is approved oral biological in market. However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.
Get The PDF Beochure of This Report : https://www.coherentmarketinsights.com/insight/request-pdf/989
Frequent research and development activities by key players for the development of novel oral biologics products and launch them in market is expected to boost global oral biologics market growth over the forecast period. For instance, Allena Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, is involved in development of Reloxaliase, a non-absorbed, orally-administered enzyme for treatment of hyperoxaluria. Currently (June 2019), Reloxaliase is in Phase 2 clinical trial. Furthermore, key players in the market are involved in strategic partnership and mergers for development of novel oral biologics products and gain its approval. Such strategic partnerships are expected to drive global oral biologics market growth.
Robust research and development activities for development of novel oral biologics is expected fuel the market growth
Key players are involved in extensive research and development of novel oral biologics for various conditions
In February 2019, researchers at Massachusetts Institute of Technology (MIT) developed a drug capsule with the potential to deliver an oral insulin named SOMA capsule, thereby replacing (or eliminating) the need to administer insulin via injections multiple times a day for patients with type 1 diabetes. The researchers stated that the drugs is currently under preclinical studies and is expected to enter clinical trials by 2022.
Increasing partnerships and collaborations by market players is expected to create conducive environment for global oral biologics market growth
Increasing number of strategic moves such as collaborations and innovations by key players is an important factor driving global oral biologics market growth in near future.
For instance, in 2016, Rani Therapeutics announced collaboration with Medimmune, a research and development subsidiary of AstraZeneca, to evaluate Rani Therapeutics’ novel oral drug delivering platform. This collaboration is expected to facilitate feasibility studies of drugs and test biologic molecules in the area of metabolic disease, to evaluate oral delivery of molecules. The objective of this collaboration is to deliver biologics orally, in order to increase compliance and improve patients’ lives globally.
Key players operating in the global oral biologics market include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc., Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.
Request Customization : https://www.coherentmarketinsights.com/insight/request-customization/989
North America is expected to hold dominant position in the market, owing to presence of major players and frequent research by them
The U.S. is expected to be most lucrative market for oral biologics in North America, as it is the biggest pharmaceutical market with high presence of major players. Furthermore, high healthcare expenditure, healthcare awareness, and high adoption rate of novel drugs make the U.S. most prominent market for oral biologics.
According to Labiotech.eu, 2018, around half of the top 100 drug sales will be biologics by 2022. Moreover, an estimated 2,700 biologics are currently in development, which means they can create a conducive biologics market post approval. However, the biological drugs are administered parentally, which can result in high treatment costs and lower adherence rates.
According to the research conducted by Rani Therapeutics in 2018, around 62% patients and 86% physicians reported that patients either skip their injection or consistently fail to inject the drug as prescribed. The research further stated that around 70% rheumatologists and 92% gastroenterologists believe that availability of pills would significantly increase patient compliance rates.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oral Biologics Market Perspective by Comprehensive Analysis, Growth Prediction to 2026 With Key Players Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Rani Therapeutics, Entera Bio, Allergan, Emisphere Technologies, Enteris BioPharma here
News-ID: 1805205 • Views: 305
More Releases from Coherent Market Insights - Biotechnology
Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy
Diabetes Vaccine Market Scrutinized in New Research 2018-2026
Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses. Diabetes vaccine is being developed to strengthen the body’s response against enterovirus
More Releases for Bio
Global Bioplastics (Bio-plastics,Bio plastics) Market 2018 - Braskem, BASF
Apex Market Reports, recently published a detailed market research study focused on the “Bioplastics (Bio-plastics,Bio plastics) Market” across the global, regional and country level. The report provides 360° analysis of “Bioplastics (Bio-plastics,Bio plastics) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Bioplastics
Bio Electronics and Bio Sensors Market Forecasts, 2017-2025
Description: The global bio electronic market is valued USD $15 billion in 2016 and is expected to grow at a CAGR of 11.6% during the forecast period 2017-2025. The market is driven by various factors such as rapid advancement in semiconductor technology, high demand in implantable medical devices, increasing prevalence of neural and cardiac diseases among others. The emerging healthcare technologies such as lab on chip, ambulatory surgical centres, and personalized devices are
Bio Simulation Technology Market
Global Bio Simulation Technology Industry Bio Simulation Technology Market is estimated at $1.01 billion in 2015 and is projected to reach $2.99 billion by 2022 growing at a CAGR of 16.6% from 2015 to 2022. Reduction in the cost of drug discovery and development and risk of failure of drug molecule are some of the factors driving the market growth. Furthermore, R&D investments in biotechnology and pharmaceutical industries, growth in the
Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021
Qyresearchreports include new market research report “Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021″ to its huge collection of research reports. This market intelligence report serves its readers with an executive-level blueprint of the global Bio-Polyethylene Terephthalate (Bio-PET) market. Data from a number of paid and unpaid sources including press releases, journals, presentations, and white papers has been taken into account for collating this report. The various factors influencing the growth of
SHANE RADBONE CORPORATE BIO
Young, dynamic and highly successful Shane founded his own business, Executive Fitness Management at age 20 in 1991. After a successful career in football that took him as high as playing for Essendon, Shane appreciated the need to have more than just sport in his portfolio. However taking his on field attitude to the corporate arena, Executive Fitness Management (EFM) grew into Australia’s largest Corporate Fitness Company. It started with
The Bio-Chromatographers’ wish
Simply high dynamic binding capacities (DBC’s) are no longer sufficient. High DBC, at high flow rates with close to 100% recovery, across a wide range of molecular weights, this is what chromatographers look for in modern ion exchange resins. “BioPro” YMC’s hugely successful ion exchange material offers exactly this. The growing user base confirms very good separation, high dynamic binding capacities and excellent recoveries for the anion as well as